Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies.
Journal: British journal of haematology
Published: September 05, 2025
Targeting Menin in T-lineage Acute Lymphoblastic Leukemia.
Journal: Molecular cancer therapeutics
Published: August 15, 2025
Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies.
Journal: American journal of hematology
Published: June 25, 2025
Hematologic complications in patients exposed to poly- ADP ribose polymerase inhibitors.
Journal: Haematologica
Published: June 20, 2025
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.
Journal: Leukemia
Published: March 03, 2025
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia.
Journal: Blood cancer journal
Published: December 09, 2024
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 09, 2024
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
Journal: Leukemia & lymphoma
Published: March 05, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Journal: American journal of hematology
Published: January 17, 2024
Last Updated: 09/26/2026